Treatment of Secondary Male Hypogonadism with Erectile Dysfunction
In men with secondary hypogonadism, erectile dysfunction is a recognised co-occurring condition that directly influences the clinical management strategy. When both are present, the treatment pathway must account for each component.
Clinical scenario
Secondary male hypogonadism in the setting of erectile dysfunction — where difficulty achieving or maintaining an erection is an active concern alongside the underlying hormonal deficit.
Approach overview
Management in this setting involves phosphodiesterase type 5 inhibitor (PDE5I) therapy as part of the structured approach, with hormonal considerations forming a key additional element of the complete regimen. The full protocol — including sequencing, specific choices, and monitoring — is available below.
References
In hypogonadal men with erectile dysfunction start with a phosphodiesterase type 5 inhibitor (PDE5I) as first line treatment and add testosterone in case of a poor response to PDE5I treatment.
View source ↗